Jennifer Kehlet Barton
Director, BIO5 Institute
Professor, Agricultural-Biosystems Engineering
Professor, BIO5 Institute
Professor, Biomedical Engineering
Professor, Electrical and Computer Engineering
Professor, Medical Imaging
Professor, Optical Sciences
Primary Department
Department Affiliations
(520) 626-0314
Work Summary
I develop new optical imaging devices that can detect cancer at the earliest stage. Optics has the resolution and sensitivity to find these small, curable lesions, and we design the endoscope that provide access to organs inside the body. .
Research Interest
Jennifer Barton, Ph.D. is known for her development of miniature endoscopes that combine multiple optical imaging techniques,particularly optical coherence tomography and fluorescence spectroscopy. She evaluates the suitability of these endoscopic techniques for detecting early cancer development in patients and pre-clinical models. She has a particular interest in the early detection of ovarian cancer, the most deadly gynecological malignancy. Additionally, her research into light-tissue interaction and dynamic optical properties of blood laid the groundwork for a novel therapeutic laser to treat disorders of the skin’s blood vessels. She has published over 100 peer-reviewed journal papers in these research areas. She is currently Professor of Biomedical Engineering, Electrical and Computer Engineering, Optical Sciences, Agriculture-Biosystems Engineering, and Medical Imaging at the University of Arizona. She has served as department head of Biomedical Engineering, Associate Vice President for Research, and is currently Director of the BIO5 Institute, a collaborative research institute dedicated to solving complex biology-based problems affecting humanity. She is a fellow of SPIE – the International Optics Society, and a fellow of the American Institute for Medical and Biological Engineering. Keywords: bioimaging, biomedical optics, biomedical engineering, bioengineering, cancer, endoscopes


Yang, M., Katz, J., Barton, J. K., Lai, W., & Jean, J. (2015). Using optical coherence tomography to examine additives in Chinese Song Jun glaze. Archaeometry, 57(5), 837-855.
Barton, J. K., Tang, S., Lim, R., & Tromberg, B. J. (2007). Simultaneous optical coherence and multiphoton microscopy of skin-equivalent tissue models - art. no. 66270X. OPTICAL COHERENCE TOMOGRAPHY AND COHERENCE TECHNIQUES III, 6627, X6270-X6270.
Bonnema, G. T., Cardinal, K. O., Williams, S. K., & Barton, J. K. (2007). Imaging stented blood vessel mimics with optical coherence tomography. LASERS IN SURGERY AND MEDICINE, 46-46.
Chandra, S., Nymeyer, A. C., Rice, P. F., Gerner, E. W., & Barton, J. K. (2017). Intermittent Dosing with Sulindac Provides Effective Colorectal Cancer Chemoprevention in the Azoxymethane-Treated Mouse Model. Cancer prevention research (Philadelphia, Pa.), 10(8), 459-466.

Sulindac is an NSAID that can provide effective chemoprevention for colorectal cancer. In this study, alternative dosing regimens of sulindac were evaluated for their chemoprevention effectiveness in the azoxymethane-treated A/J mouse model of colorectal cancer. High-resolution endoscopic optical coherence tomography was utilized to time-serially measure tumor number and tumor burden in the distal colon as the biological endpoints. Four treatment groups were studied: (i) daily for 20 weeks (sulindac-daily); (ii) for 2 weeks, then no sulindac for 2 weeks, cycle repeated 5 times (sulindac-2); (iii) for 10 weeks ("on"), then no sulindac for 10 weeks ("off"; sulindac-10); and (iv) no sulindac (sulindac-none). Sulindac-2 and sulindac-daily had statistically significantly lower final tumor counts and slopes (change in number of tumors per week) when compared with sulindac-none (P

Barton, J. K., Barton, J. K., Marion, S. L., Rice, P. F., Utzinger, U., Brewer, M. A., Hoyer, P. B., & Barton, J. K. (2013). Two-photon excited fluorescence imaging of endogenous contrast in a mouse model of ovarian cancer. Lasers in surgery and medicine, 45(3).

Ovarian cancer has an extremely high mortality rate resulting from poor understanding of the disease. In order to aid understanding of disease etiology and progression, we identify the endogenous fluorophores present in a mouse model of ovarian cancer and describe changes in fluorophore abundance and distribution with age and disease.